在诊所测试困境:从基于生物标志物的药物开发中吸取的经验教训
Sahar Barjesteh van Waalwijk van Doorn-Khosrovani1, Olga Kholmanskikh Van Criekingen2, Simone Koole3
1Department of Medical Oncology, Leiden University Medical Centre, Leiden, the Netherlands; Medical Department, CZ Health Insurance, Tilburg, the Netherlands.
Cancer cell
|June 11, 2024
概括
标准化复杂的生物标志物用于多聚基酸聚合酶 (PARP) 抑制剂治疗至关重要. 这项研究提出了协调定义和性能标准的措施,以确保公平的准确医学获取.
科学领域:
- 生物标志物发现和验证
- 精准医学是一门精准的医学.
- 瘤学 诊断 诊断 瘤学
背景情况:
- 存在多种诊断测试,以确定符合多ADP-糖) 聚合酶 (PARP) 抑制剂治疗的患者.
- 目前的生物标志物测试缺乏协调,具有不同的切断点和未解决的空间/时间变化.
- 这种异质性使单个试验的临床有用性评估和治疗统一性变得复杂.
研究的目的:
- 建议在选择PARP抑制剂治疗中对生物标志物定义进行标准化措施.
- 为相关诊断试验建立最低分析性能特征.
- 促进公平和可持续地获得精准医学.
主要方法:
- 对用于PARP抑制剂治疗的现有生物标记测定进行审查和分析.
- 制定一个协调生物标志物定义的框架.
- 关于诊断试验分析性能最低标准的建议.
主要成果:
- 在目前对PARP抑制剂的生物标志物测试中确定了关键挑战.
- 概述了在不同试验中对生物标志物定义进行调整的策略.
- 建议用于诊断测试验证的特定性能标准.
结论:
- 生物标志物定义和分析性能的协调对于可靠的PARP抑制剂治疗选择至关重要.
- 标准化诊断将提高测试的临床效用,并确保一致的治疗决策.
- 实施这些措施将促进公平获得个性化癌症治疗.
相关概念视频
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
125
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
125
Drug Discovery: Overview
7.8K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.8K
Preclinical Development: Overview
4.4K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.4K
Clinical Trials: Overview
2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K


